Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

AC0010, a Novel BTK Inhibitor, Exerts Anti-Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML

Jie Jin, MD PhD, Shujuan Huang

Blood (2018) 132 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2018-99-114350

Published: 2018

Journal Articles

HH-002 Effectively Suppresses Myeloproliferative Neoplasm Phenotypes in JAK2V617F Transgenic Mice

Wan-Ting Ho, Wanke Zhao, Paul Hallenbeck, Frank Rong, Zhizhuang Joe Zhao, PhD

Blood (2015) 126 (23): 4095.

https://doi.org/10.1182/blood.V126.23.4095.4095

Published: 2015

Journal Articles

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Magdalena Klanova, MD, Ladislav Andera, M.Sc. PhD, Jan Soukup, MDPhD, Brazina Jan, M.Sc., Jan Svadlenka, M.Sc., Simona Benesova, M.Sc., Dana Prukova, M.Sc. PhD, Dana Vejmelkova, M.Sc., Radek Jaksa, MD, Karel Helman, PhD, Petra Vockova, MD, Lucie Lateckova, MD, Jan Molinsky, MD PhD, Bokang Maswabi, MD, Mahmudul Alam, PhD, Roman Kodet, Prof. MD, Marek Trneny, Pavel Klener, MD, PhD

Blood (2014) 124 (21): 3645.

https://doi.org/10.1182/blood.V124.21.3645.3645

Published: 2014

Journal Articles

Visualizing the Effects of Chemicals On Hematopoietic Stem Cell Engraftment in an Endogenous Niche

Owen J. Tamplin, PhD, Ellen Durand, Pulin Li, PhD, Leonard I. Zon, MD

Blood (2012) 120 (21): 506.

https://doi.org/10.1182/blood.V120.21.506.506

Published: 2012

Journal Articles

Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

Rong Chen, Lei Guo, Yuling Chen, Yingjun Jiang, William G. Wierda, William Plunkett

Blood (2011) 117 (1): 156–164.

https://doi.org/10.1182/blood-2010-01-262808

Published: 2011

Includes: Supplemental data

Journal Articles

Pre- and Post-National Coverage Determination (NCD) Hematologic Outcomes and Blood Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA): Results From a Multicenter Chart Review.

David H. Henry, MD, Corey J. Langer, MD, FACP, R. Scott McKenzie, MD, Catherine Tak Piech, MBA, Mekré Senbetta, PharmD, Kathy L. Schulman, MA, Edward J. Stepanski, PhD

Blood (2009) 114 (22): 2491.

https://doi.org/10.1182/blood.V114.22.2491.2491

Published: 2009

Journal Articles

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

Mohamad Ayoubi, MD, Hagop M. Kantarjian, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Jody Hiteshew, Zeev Estrov, MD, Jorge Cortes-Franco, MD

Blood (2009) 114 (22): 2193.

https://doi.org/10.1182/blood.V114.22.2193.2193

Published: 2009

Journal Articles

A Homoharringtonine-Based Protocol Is Superior to Daunorubicin and Idarubicin-Based Protocols in Elderly Patients with Newly-Diagnosed Acute Myeloid Leukemia with Comparable Effects and Low Toxicities: Experience in a Chinese Center.

Jianmin Wang, MD, Shuqing Lü, Jianmin Yang, Xianmin Song, Li Chen, Jun Hou, Weiping Zhang, Chongmei Huan, Xiong Ni, Huiying Qiu

Blood (2008) 112 (11): 1946.

https://doi.org/10.1182/blood.V112.11.1946.1946

Published: 2008

Journal Articles

Homoharringtonine Based Triple-Drug Regimen as Induction Chemotherapy for De Novo Acute Myelogenous Leukemia.

Jie Jin, Wenbin Qian, Hui Liu, Daozi Jian, Wenyuan Mai, Hongyan Tong, Haitao Men

Blood (2006) 108 (11): 2002.

https://doi.org/10.1182/blood.V108.11.2002.2002

Published: 2006

Journal Articles

Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS).

Gautam Borthakur, MD, Hagop Kantarjian, MD, Elihu Estey, MD, Srdan Verstovsek, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2005) 106 (11): 4903.

https://doi.org/10.1182/blood.V106.11.4903.4903

Published: 2005

Journal Articles

HHT-Induced Cell Apoptosis Is Associated with Reduction of Survivin mRNA Expression.

Zhen Cai, PhD, MD, Hanying Bao

Blood (2004) 104 (11): 4364.

https://doi.org/10.1182/blood.V104.11.4364.4364

Published: 2004

Journal Articles

Homoharringtonine in Combination with Imatinib for Patients with CML Who Have Achieved Partial or Complete Cytogenetic Responses.

Rifca Le Dieu, MD, Marco Bua, MD, Catharina Andreasson, Eduardo Olavarria, MD, Jonh M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2004) 104 (11): 1012.

https://doi.org/10.1182/blood.V104.11.1012.1012

Published: 2004

Journal Articles

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Susan O’Brien, Hagop Kantarjian, Charles Koller, Eric Feldman, Miloslav Beran, Michael Andreeff, Sergio Giralt, Bruce Cheson, Michael Keating, Emil Freireich, Mary Beth Rios, Moshe Talpaz

Blood (1999) 93 (12): 4149–4153.

https://doi.org/10.1182/blood.V93.12.4149

Published: 1999

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

AC0010, a Novel BTK Inhibitor, Exerts Anti-Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML

HH-002 Effectively Suppresses Myeloproliferative Neoplasm Phenotypes in JAK2V617F Transgenic Mice

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Visualizing the Effects of Chemicals On Hematopoietic Stem Cell Engraftment in an Endogenous Niche

Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

Pre- and Post-National Coverage Determination (NCD) Hematologic Outcomes and Blood Utilization in Cancer Patients with Chemotherapy-Induced Anemia (CIA): Results From a Multicenter Chart Review.

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

A Homoharringtonine-Based Protocol Is Superior to Daunorubicin and Idarubicin-Based Protocols in Elderly Patients with Newly-Diagnosed Acute Myeloid Leukemia with Comparable Effects and Low Toxicities: Experience in a Chinese Center.

Homoharringtonine Based Triple-Drug Regimen as Induction Chemotherapy for De Novo Acute Myelogenous Leukemia.

Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS).

HHT-Induced Cell Apoptosis Is Associated with Reduction of Survivin mRNA Expression.

Homoharringtonine in Combination with Imatinib for Patients with CML Who Have Achieved Partial or Complete Cytogenetic Responses.

Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only